Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

GSX, AVOT, KBX, MSLP, RNN - Stock News & Alerts! Presented by



Gasco Energy Inc. (AMEX:GSX) announced that on November 19, 2010 it received notice that it has resolved its NYSE Amex continued listing deficiencies and is now in compliance with all NYSE Amex continued listing standards. Gasco's regaining of compliance is based upon an NYSE Amex review of publicly available information. Specifically, the Company has resolved the continued listing deficiency with respect to Section 1003(a)(iii) of the NYSE Amex Company Guide, with respect to stockholders' equity requirements as referenced in the NYSE Amex's notice dated June 25, 2009.

The November 19, 2010 notice also stated that, as is the case for all listed issuers, Gasco's continued listing eligibility will be assessed on an ongoing basis.

Denver-based Gasco Energy, Inc. is a natural gas and petroleum exploitation, development and production company engaged in locating and developing hydrocarbon resources, primarily in the Rocky Mountain region.


American Video Teleconferencing Corp. Signs Option Agreement

American Video Teleconferencing Corp. (Pink Sheets:AVOT) “the company”, is pleased to announce that it has signed an option agreement for three gold bearing claim blocks situated in the northern mining district of Saskatchewan, Canada.

Assays taken in 2008 on selected samples returned repeatable high grade gold values of 7gms/ton (.25oz) to 112.9gms/ton (3.99oz/ton). The property owners did random sampling in June 2007 and had an assay of 933gms/ton (32.9oz/ton) of gold from one of the samples and that prompted the writing of a technical report on the project that was prepared in compliance with the National Instrument 43-101 and Form 43-101F1 and was issued on November, 28 2008.

The writer was Duncan Bain P Geo. who resides in London Ontario, Canada. Samples that were taken as part of a work program done on the property were sent to an ISO-certified assay laboratory based in Saskatoon, Saskatchewan Canada.

The project is 1385 hectares in area and covers several documented nickel-copper and gold showings and land in proximity to lake sediment geochemical and biogeochemical anomalies. All these are part of the Snowbird Tectonic Zone which is a major tectonic structure and extends for more than 2,000 kilometres.

Access to the project is currently by float or ski equipped aircraft or by helicopter to Stony Rapids which is accessible by commercial aircraft from the major cities of Saskatoon or Regina in southern Saskatchewan. The expenditures for the 2010-2011 work program will be paid by the property owners due to an arrangement reached in the option agreement with the issuance of 1.2 million restricted shares (144).

The company, after a lengthy search and after careful due diligence, believes this is going to be one of the most active areas for Rare Earths exploration and our holdings are in the same geological setting as the 48% Rare Earths showing. Rare Earths are in huge demand especially in the United States as China is closing off its exports of these strategic metals to less than 5% of its production. The company will aggressively continue to search world wide for opportunities in Precious, Base and Rare Earths metal projects.


Kimber Resources Inc. (AMEX:KBX) is pleased to announce assay results of a program of comprehensive channel sampling of surface trenches from the Carmen deposit at its Monterde Project in Mexico. The results of this sampling program demonstrate continuity of high grade gold-silver mineralization to surface, as well as potential extensions to the high grade mineralization to the south of prior exploration.
Kimber owns mineral concessions covering in excess of 39,000 hectares in the prospective Sierra Madre gold-silver belt, including the Monterde property, where three gold-silver mineral resources have already been defined. The most advanced of these, the Carmen deposit, has been extensively drilled and has undergone detailed geologic modeling.


MusclePharm Corporation (OTC:MSLP), has been invited to present at the upcoming HIV DART(NYSE:TM) 2010: Frontiers in Drug development for Antiretroviral Therapies Conference being held from December 7-10, 2010 in Los Cabos, Mexico.

This innovative conference, HIV DART(TM) 2010, will uniquely blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community an increased understanding of the current and future challenges in therapeutics for HIV infection. This brings leaders in the research community together to advance the medical communities knowledge of the ongoing drug development processes in antiretroviral research.

At this year’s HIV DART(TM) 2010 Conference, MusclePharm will present its results on the use of its product, Recon, in HIV patients. Early results show that Recon may help prevent the onset of wasting syndrome by facilitating the growth and maintenance of muscle mass in people living with HIV, which has been associated with antiretroviral drug resistance.

Recon contains important amino acids, assisting in reaching the higher levels of nutrition required for people living with HIV. MusclePharm’s Recon Nutritional Supplement is easily digestible, helps the absorption of amino acids and proteins. It contains essential minerals, digestive enzymes, Glutamine and other metabolic agents that maximize recovery, protein synthesis and endurance.

MusclePharm recently presented its findings on the use of Recon to prevent and treat wasting syndrome in HIV patients at XVIII International AIDS Conference this past July in Vienna, Austria at the Research Advances satellite symposium sponsored by the National Association of People with AIDS and The AIDS Institute. The Company also presented this past week at the 138th Annual Meeting of the American Public Health Association in Denver, CO.

MusclePharm is currently striving to obtain Medicaid approval for the product in states with designated Eligible Metropolitan Areas under the Ryan White HIV/AIDS Treatment Modernization Act.


Rexahn Pharmaceuticals, Inc. (AMEX:RNN) a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry [18:7966-7974, 2010] on the anticancer activity of quinoxalinyl-piperazine compounds. The study demonstrates that the quinoxalinyl-piperazine compounds strongly inhibit the growth of human cancer cells through programmed cell death (apoptosis), including paclitaxel (Taxol®) resistant HCT-15 human colorectal cancer cells. Those compounds also display the synergistic cytotoxic effect when combined with several known cancer drugs such as paclitaxel, doxorubicin, cisplatin, gemcitabine or 5-fluorouracil in cancer cells.

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous system (NYSE:CNS) disorders, sexual dysfunction, and other unmet medical needs in the United States.


Sign-Up For Free Stock Alerts At

business Card 3


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more at ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) anticipates to receive 2,000,000 shares of (144) restricted common stock of American Video Teleconferencing Corp. (OTCPK:AVOT) from the company for 12 months IR Services. Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for 30 (thirty) days of advertising for MusclePharm Corporation (OTCQB:MSLP)